Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin

John Wong, Logan B. Smith, Eli A. Magun, Thomas Engstrom, Kirsten Kelley-Howard, Dakshina M. Jandhyala, Cheleste M. Thorpe, Bruce E. Magun, Lisa Wood

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-related fatigue, have been associated with inflammatory cytokines, many of which are regulated by mitogen-activated protein kinases (MAPKs). ZAK is an upstream kinase of the MAPK cascade. Using mouse primary macrophages cultured from ZAK-deficient mice, we demonstrated that ZAK is required for the activation of JNK and p38 MAPK by doxorubicin. Nilotinib, ponatinib and sorafenib strongly suppressed doxorubicin-mediated phosphorylation of JNK and p38 MAPK. In addition, these small molecule kinase inhibitors blocked the expression of IL-1β, IL-6 and CXCL1 RNA and the production of these proteins. Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1β RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone. Therefore, by reducing the production of inflammatory mediators, the inhibitors identified in the current study may be useful in minimizing the side effects of doxorubicin and potentially other chemotherapeutic drugs.

Original languageEnglish (US)
Pages (from-to)56-63
Number of pages8
JournalCancer Biology and Therapy
Volume14
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Doxorubicin
Phosphotransferases
JNK Mitogen-Activated Protein Kinases
p38 Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinases
Interleukin-1
Interleukin-6
RNA
Second Primary Neoplasms
Fatigue
Blood Proteins
Macrophages
Phosphorylation
Cytokines
Liver
Pharmaceutical Preparations
Proteins
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Keywords

  • Cytokines
  • Doxorubicin
  • MAPK
  • Nilotinib
  • Ponatinib
  • Sorafenib
  • ZAK

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Wong, J., Smith, L. B., Magun, E. A., Engstrom, T., Kelley-Howard, K., Jandhyala, D. M., ... Wood, L. (2013). Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin. Cancer Biology and Therapy, 14(1), 56-63. https://doi.org/10.4161/cbt.22628

Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin. / Wong, John; Smith, Logan B.; Magun, Eli A.; Engstrom, Thomas; Kelley-Howard, Kirsten; Jandhyala, Dakshina M.; Thorpe, Cheleste M.; Magun, Bruce E.; Wood, Lisa.

In: Cancer Biology and Therapy, Vol. 14, No. 1, 01.2013, p. 56-63.

Research output: Contribution to journalArticle

Wong, J, Smith, LB, Magun, EA, Engstrom, T, Kelley-Howard, K, Jandhyala, DM, Thorpe, CM, Magun, BE & Wood, L 2013, 'Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin', Cancer Biology and Therapy, vol. 14, no. 1, pp. 56-63. https://doi.org/10.4161/cbt.22628
Wong J, Smith LB, Magun EA, Engstrom T, Kelley-Howard K, Jandhyala DM et al. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin. Cancer Biology and Therapy. 2013 Jan;14(1):56-63. https://doi.org/10.4161/cbt.22628
Wong, John ; Smith, Logan B. ; Magun, Eli A. ; Engstrom, Thomas ; Kelley-Howard, Kirsten ; Jandhyala, Dakshina M. ; Thorpe, Cheleste M. ; Magun, Bruce E. ; Wood, Lisa. / Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin. In: Cancer Biology and Therapy. 2013 ; Vol. 14, No. 1. pp. 56-63.
@article{efe46ad45db74fb285c605691cfdbb65,
title = "Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin",
abstract = "The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-related fatigue, have been associated with inflammatory cytokines, many of which are regulated by mitogen-activated protein kinases (MAPKs). ZAK is an upstream kinase of the MAPK cascade. Using mouse primary macrophages cultured from ZAK-deficient mice, we demonstrated that ZAK is required for the activation of JNK and p38 MAPK by doxorubicin. Nilotinib, ponatinib and sorafenib strongly suppressed doxorubicin-mediated phosphorylation of JNK and p38 MAPK. In addition, these small molecule kinase inhibitors blocked the expression of IL-1β, IL-6 and CXCL1 RNA and the production of these proteins. Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1β RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone. Therefore, by reducing the production of inflammatory mediators, the inhibitors identified in the current study may be useful in minimizing the side effects of doxorubicin and potentially other chemotherapeutic drugs.",
keywords = "Cytokines, Doxorubicin, MAPK, Nilotinib, Ponatinib, Sorafenib, ZAK",
author = "John Wong and Smith, {Logan B.} and Magun, {Eli A.} and Thomas Engstrom and Kirsten Kelley-Howard and Jandhyala, {Dakshina M.} and Thorpe, {Cheleste M.} and Magun, {Bruce E.} and Lisa Wood",
year = "2013",
month = "1",
doi = "10.4161/cbt.22628",
language = "English (US)",
volume = "14",
pages = "56--63",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin

AU - Wong, John

AU - Smith, Logan B.

AU - Magun, Eli A.

AU - Engstrom, Thomas

AU - Kelley-Howard, Kirsten

AU - Jandhyala, Dakshina M.

AU - Thorpe, Cheleste M.

AU - Magun, Bruce E.

AU - Wood, Lisa

PY - 2013/1

Y1 - 2013/1

N2 - The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-related fatigue, have been associated with inflammatory cytokines, many of which are regulated by mitogen-activated protein kinases (MAPKs). ZAK is an upstream kinase of the MAPK cascade. Using mouse primary macrophages cultured from ZAK-deficient mice, we demonstrated that ZAK is required for the activation of JNK and p38 MAPK by doxorubicin. Nilotinib, ponatinib and sorafenib strongly suppressed doxorubicin-mediated phosphorylation of JNK and p38 MAPK. In addition, these small molecule kinase inhibitors blocked the expression of IL-1β, IL-6 and CXCL1 RNA and the production of these proteins. Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1β RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone. Therefore, by reducing the production of inflammatory mediators, the inhibitors identified in the current study may be useful in minimizing the side effects of doxorubicin and potentially other chemotherapeutic drugs.

AB - The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-related fatigue, have been associated with inflammatory cytokines, many of which are regulated by mitogen-activated protein kinases (MAPKs). ZAK is an upstream kinase of the MAPK cascade. Using mouse primary macrophages cultured from ZAK-deficient mice, we demonstrated that ZAK is required for the activation of JNK and p38 MAPK by doxorubicin. Nilotinib, ponatinib and sorafenib strongly suppressed doxorubicin-mediated phosphorylation of JNK and p38 MAPK. In addition, these small molecule kinase inhibitors blocked the expression of IL-1β, IL-6 and CXCL1 RNA and the production of these proteins. Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1β RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone. Therefore, by reducing the production of inflammatory mediators, the inhibitors identified in the current study may be useful in minimizing the side effects of doxorubicin and potentially other chemotherapeutic drugs.

KW - Cytokines

KW - Doxorubicin

KW - MAPK

KW - Nilotinib

KW - Ponatinib

KW - Sorafenib

KW - ZAK

UR - http://www.scopus.com/inward/record.url?scp=84872158812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872158812&partnerID=8YFLogxK

U2 - 10.4161/cbt.22628

DO - 10.4161/cbt.22628

M3 - Article

VL - 14

SP - 56

EP - 63

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 1

ER -